chemoinformatics/covalent-design/SKILL.md
Designs covalent inhibitors and warheads targeting cysteine, lysine, serine, threonine, tyrosine, and aspartate residues, with explicit handling of warhead reactivity (acrylamide, chloroacetamide, vinyl sulfone, sulfonyl fluoride, fluorosulfate, aldehyde, boronate, nitrile), reversibility (kinact/Ki, t_residence), glutathione (GSH) stability, intrinsic reactivity assays, and covalent docking (DOCKovalent, GOLD, HCovDock). Use when designing covalent inhibitors for targeted covalent inhibition (TCI), KRAS G12C-style approaches, or rationalizing covalent SAR.
npx skillsauth add GPTomics/bioSkills bio-covalent-designInstall this skill globally with one command. Works with Claude Code, Cursor, and Windsurf.
3 of 9 scanners reported clean
Some scanners were skipped, did not run, or reported a non-clean status. Review each row below.
Reference examples tested with: RDKit 2024.09+, OpenEye / AutoDock Vina 1.2+ (for covalent extensions), GOLD (commercial), DOCKovalent (web service), HCovDock 1.0+.
Before using code patterns, verify installed versions match. If versions differ:
pip show rdkit then help(rdkit.Chem) to check signaturesIf code throws ImportError, AttributeError, or TypeError, introspect the installed package and adapt the example to match the actual API rather than retrying.
Design molecules that form covalent bonds with target protein residues. Clinically validated targeted covalent inhibitors include KRAS G12C inhibitors (sotorasib, adagrasib), BTK inhibitors (ibrutinib), and EGFR inhibitors (osimertinib). Covalent design requires balancing intrinsic reactivity (must form bond) vs selectivity (only the intended residue), reversibility (irreversible vs reversible covalent), and drug-likeness (warheads can hurt PK).
For warhead substructure filtering (in non-covalent contexts), see chemoinformatics/substructure-search. For non-covalent docking, see chemoinformatics/virtual-screening. For pose validation, see chemoinformatics/pose-validation.
| Residue | Nucleophile | Example compatible warheads | Design note | |---------|-------------|-----------------------------|-------------| | Cysteine | Thiol / thiolate | Acrylamide, haloacetamide, nitrile | Commonly targeted; local pKa and geometry control reactivity | | Lysine | Amine | Sulfonyl fluoride, aldehyde | Aldehydes can form reversible imines with amines | | Serine | Alcohol / alkoxide | β-lactam, boronate | Often requires catalytic activation | | Threonine | Alcohol / alkoxide | Boronate | Context-dependent and less commonly targeted | | Tyrosine | Phenol / phenolate | Sulfonyl fluoride, fluorosulfate | Local environment strongly affects reaction | | Aspartate/Glutamate | Carboxylate | Residue-specific electrophiles require experimental validation | Do not infer aldehyde Schiff-base formation with carboxylates |
Cysteine is frequently targeted because its thiol/thiolate can be nucleophilic and its local environment can support selective proximity-driven reaction. GSH and off-target cysteines are competing thiols, not intrinsically distinguishable from the target by the warhead alone; the complete ligand's recognition, exposure, and intrinsic reactivity determine selectivity.
| Warhead | SMARTS pattern | Reactivity | Reversibility | Cys-selective |
|---------|----------------|------------|---------------|----------------|
| Acrylamide | [CX3](=[OX1])([NX3])[CX3]=[CX3] | Moderate (Michael acceptor) | Usually irreversible | Often Cys-directed |
| Chloroacetamide | [CX3](=[OX1])([NX3])[CH2]Cl | High (SN2) | Irreversible | Often Cys-directed |
| α-haloketone | [CX3](=O)C[F,Cl,Br] | Very high | Irreversible | Yes (but reactive) |
| Vinyl sulfone | S(=O)(=O)C=C | Moderate (Michael) | Irreversible | Yes |
| Sulfonyl fluoride | S(=O)(=O)F | Moderate | Irreversible | Lys/Tyr/Ser |
| Fluorosulfate (SuFEx) | OS(=O)(=O)F | Moderate | Irreversible | Tyr/Lys |
| Aldehyde | [CX3H1](=O) | Variable | Often reversible (covalent equilibrium) | Context-dependent Cys/Lys/Ser chemistry |
| Boronate (B-OH or B(OH)2) | B(O)O | Moderate | Reversible | Ser/Thr |
| Nitrile | C#N | Low | Reversible (Cys-S adduct) | Cys |
| Epoxide | C1OC1 | High | Irreversible | Cys/Lys/Asp |
| α,β-unsaturated ketone | [CX3](=O)C=C | Moderate (Michael) | Irreversible | Cys |
| Isothiocyanate | N=C=S | High | Irreversible | Cys/Lys |
| Maleimide | O=C1N(C(=O)C=C1) | Often high | Commonly irreversible under assay conditions | Often Cys-directed |
| Cysteine-selective heterocycle | various | Moderate | Variable | Yes (designed) |
Practical hierarchy: Acrylamides are common attenuated electrophiles in cysteine-directed TCIs, including KRAS G12C, EGFR, and BTK programs. Haloacetamides are generally more intrinsically reactive, but actual selectivity must be measured for the complete molecule and target context.
| Goal | Warhead choice | Reactivity tier | |------|----------------|-----------------| | Cysteine TCI program | Acrylamide is one common starting class | Measure complete-compound target and intrinsic reactivity | | Cysteine probe program | Haloacetamides are one common class | Higher intrinsic reactivity can aid labeling but requires selectivity profiling | | Lysine TCI (uncommon) | Sulfonyl fluoride | Moderate | | Tyrosine TCI | Fluorosulfate (SuFEx) | Moderate | | Reversible covalent | Warhead with demonstrated reversible adduct chemistry, such as selected cyanoacrylamides, aldehydes, nitriles, or boronates | Confirm reversibility experimentally | | Activity-based protein profiling (ABPP) | Iodoacetamide / chloroacetamide | Very high | | Boronic acid inhibitor (proteasome) | Boronate | Reversible | | Aldehyde inhibitor (calpain) | Aldehyde | Reversible covalent |
Covalent inhibition kinetics:
For irreversible two-step inhibition that follows the corresponding kinetic model, report fitted kinact, Ki, and kinact/Ki rather than only a time-dependent IC50. Two compounds with the same IC50 can have different kinetic components:
Because kinact/Ki depends on the target, construct, assay conditions, and kinetic model, compare values within a matched assay series and alongside exposure, intrinsic reactivity, target engagement, and selectivity. Reversible-covalent systems may require different mechanistic models and residence-time or washout measurements.
Before committing to a warhead, measure intrinsic reactivity (off-target risk):
# Generic GSH stability assay readout - measure half-life of warhead with 10 mM GSH
# kinact_GSH from time-course of warhead disappearance
Do not assign a universal GSH half-life from the warhead name alone. Substitution, electronics, ionization, solubility, and assay conditions can change the observed rate. Report the GSH concentration, buffer, temperature, analytical method, and fitted half-life or second-order rate constant for the complete compound.
| Tool | Approach | Strength | Fails when | |------|----------|----------|------------| | DOCKovalent (London et al 2014 Nat Chem Biol 10:1066) | Constraint-based DOCK | Free, well-validated | Browser-based; small library | | GOLD covalent (CCDC) | GOLD with covalent constraint | Commercial; selectivity | License cost | | AutoDock 4 covalent | AD4 with covalent bond | Open source | Slower than Vina | | CovDock (Schrödinger) | Glide-based + covalent | Commercial two-stage covalent docking workflow | License cost | | MOE covalent | Triposite Discovery | Commercial | License cost | | HCovDock (Wu Q, Huang S-Y 2023 Briefings Bioinform 24:bbac559) | Hierarchical fragment + covalent | Open; supports many residues | Newer, less validated | | ICM-Pro covalent | Active site grid + covalent | Commercial; metal centers | License cost |
For open-source covalent docking, HCovDock (2023) is the modern alternative; DOCKovalent is the longstanding standard.
Goal: Decorate a co-crystal scaffold with a cysteine-targeting warhead and rank candidates by covalent efficiency.
Approach: Load scaffold SMILES, enumerate acrylamide-bearing analogs, filter by reactivity selectivity, dock under covalent constraint, and rank by kinact/Ki surrogates.
from rdkit import Chem
# Step 1: scaffold from co-crystal (4LRW or AMG510)
scaffold_smi = 'c1ccc(C(=O)NCC)cc1' # generic valid scaffold for code illustration
scaffold = Chem.MolFromSmiles(scaffold_smi)
# Step 2: enumerate analogs with acrylamide warhead
def add_acrylamide(scaffold, attachment_atom_idx):
"""Project hook: attach a mapped acrylamide with an audited reaction."""
raise NotImplementedError(
'Provide a project-specific mapped reaction and validate atom mapping, '
'valence, regioisomer identity, and product sanitization.'
)
# Step 3: filter for reactive group selectivity
# Step 4: dock with DOCKovalent / GOLD covalent / HCovDock
# Step 5: rank by kinact/Ki surrogate (compute reactive Michael acceptor reactivity)
For ranking warheads without wet-lab data:
| Descriptor | Use case |
|------------|----------|
| LUMO energy (DFT) | Michael acceptor reactivity (lower LUMO = more reactive) |
| Electrophile partial charge | SN2 reactivity |
| RDKit rdMolDescriptors.CalcLabuteASA | Steric accessibility |
| Experimentally supported binding pose or validated docking model | Geometric fit to reactive residue |
Goal: Record alpha-carbon substitution as a structural feature for an acrylamide series.
Approach: Parse the SMILES, locate the acrylamide substructure, and count neighbors on the alpha carbon outside the matched warhead. This count is not a LUMO estimate or a stand-alone reactivity prediction; substituent electronics and the rest of the molecule must be considered, and reactivity should be measured.
def acrylamide_alpha_substitution_count(smi):
mol = Chem.MolFromSmiles(smi)
if mol is None:
return None
acryl_pat = Chem.MolFromSmarts(
'[CX3:1](=[OX1:2])([NX3:3])[CX3:4]=[CX3:5]'
)
matches = mol.GetSubstructMatches(acryl_pat, uniquify=True)
if not matches:
return None
alpha_query_idx = next(
atom.GetIdx() for atom in acryl_pat.GetAtoms()
if atom.GetAtomMapNum() == 4
)
alpha_c = mol.GetAtomWithIdx(matches[0][alpha_query_idx])
n_subs = len([n for n in alpha_c.GetNeighbors() if n.GetIdx() not in matches[0]])
return n_subs
For a reactivity model, use experimentally measured rates or a validated quantum-chemical workflow; a single frontier-orbital energy is not sufficient on its own.
Trigger: A warhead/residue pairing is assumed from a broad class label.
Mechanism: Reaction depends on the residue microenvironment, electrophile, binding pose, and catalytic assistance; a class label does not establish residue selectivity.
Symptom: No covalent adduct observed despite docking pose.
Fix: Use literature-supported residue/warhead chemistry as a hypothesis, then verify site-specific adduct formation and competing reactivity experimentally.
Trigger: Chloroacetamide in drug-candidate context.
Mechanism: Excess intrinsic electrophile reactivity can increase reaction with GSH and off-target nucleophiles.
Symptom: Toxicity in cell-based assays; non-specific binding signal.
Fix: Test a less intrinsically reactive electrophile and measure its GSH and target-reaction kinetics; alpha substitution can tune behavior but does not guarantee selectivity or stability.
Trigger: The ligand's reactive atom is poorly positioned relative to the target nucleophile.
Mechanism: Covalent reaction requires warhead-specific distance and approach geometry between the electrophilic atom and the nucleophilic atom (Cys Sγ for cysteine).
Symptom: No covalent labeling in mass spec despite predicted docking.
Fix: Identify the reaction atoms, inspect the pre-reaction Sγ-to-electrophile distance and reaction-specific angles, and use a docking protocol parameterized for that reaction. Do not substitute Cβ distance for the reacting sulfur.
Trigger: Designed irreversible TCI but warhead is reversible.
Mechanism: Reversibility depends on the complete electrophile, adduct chemistry, protein environment, and assay timescale; class-level labels are only hypotheses.
Symptom: Activity wanes after substrate washout in cellular assays.
Fix: Select chemistry with demonstrated behavior in the intended context and verify reversibility by dilution, washout, intact-protein MS, or another suitable experiment.
Trigger: Optimizing for IC50 instead of kinact/Ki.
Mechanism: Compounds with same IC50 differ in covalent efficiency.
Symptom: Compounds with similar endpoint IC50 values show different time-dependent target engagement or pharmacodynamic duration.
Fix: Fit a mechanistically appropriate kinetic model. Use kinact/Ki for qualifying irreversible two-step systems; use equilibrium, residence-time, or washout measurements where appropriate for reversible covalent systems.
Trigger: Default DOCKovalent run.
Mechanism: Covalent constraint forces docking; many ligands "succeed" but are unrealistic.
Symptom: Many compounds pass docking; few label in vitro.
Fix: Review measured/validated reactivity, reaction-atom geometry (Cys Sγ for cysteine), non-covalent recognition, strain, and site-specific experimental labeling.
| Aspect | Irreversible | Reversible covalent | |--------|--------------|---------------------| | Examples | KRAS G12C (acrylamide), BTK (ibrutinib) | Boronate (bortezomib), aldehyde (calpain inhibitors) | | Toxicity profile | Off-target Cys labeling potential | Off-target equilibrium | | Resistance mechanism | Mutation of reactive Cys | Mutation reduces affinity | | Design decision | Consider duration of target engagement, safety, exposure, and resistance | Consider equilibrium, residence time, and recovery after washout |
| Symptom | Cause | Fix | |---------|-------|-----| | Warhead not matching SMARTS | Different stereochemistry or charged | Use canonicalized + neutral SMARTS | | DOCKovalent rejects ligand | No suitable Cys in pocket | Re-check residue accessibility | | GSH adduct dominates | Warhead too reactive | Use less reactive warhead; or alpha-substitute | | Off-target labeling in cells | Promiscuous warhead | Iterate warhead reactivity vs selectivity | | Docking pose but no labeling | Geometric mismatch | Distance check; rotamer search | | Intended irreversible inhibitor shows recovery after washout | Adduct chemistry is reversible or covalent reaction is incomplete | Re-evaluate the mechanism and fit the appropriate kinetic model | | HCovDock fails on PROTAC | Tool optimized for monomer covalent | Use specialized tools for bivalent |
development
Installs 425 bioinformatics skills covering sequence analysis, RNA-seq, single-cell, variant calling, metagenomics, structural biology, and 56 more categories. Use when setting up bioinformatics capabilities or when a bioinformatics task requires specialized skills not yet installed.
testing
Chains a somatic (tumor-normal) SNV/indel and structural-variant pipeline end to end with GATK Mutect2 (or Strelka2), wiring the somatic-specific machinery - panel-of-normals and gnomAD germline-resource priors, GetPileupSummaries/CalculateContamination, and LearnReadOrientationModel FFPE/oxoG orientation-bias filtering fed into FilterMutectCalls. Use when calling somatic mutations from a tumor-normal pair (or tumor-only with PoN caveats), deciding which artifact filter removes which class of false positive, reasoning about VAF/purity/ploidy and clonal-vs-subclonal detection, adding somatic SV/CNV or TMB/MSI/signatures, or routing variants to AMP/ASCO/CAP tier and oncogenicity interpretation (never germline ACMG).
development
End-to-end pooled and single-cell CRISPR screen analysis from FASTQ to hit genes. Orchestrates library design QC, guide counting, six-stage screen QC (plasmid Gini, replicate Pearson, CEGv2 PR-AUC, copy-number artifact), method-appropriate hit calling across MAGeCK RRA/MLE, BAGEL2, drugZ, JACKS, and Chronos, cancer-cell-line copy-number correction (CRISPRcleanR / Chronos), batch correction for multi-batch screens, and the specialized branches for combinatorial paralog screens, single-cell Perturb-seq, base-editor variant-function screens, prime-editor screens, and in vivo bottleneck-aware screens. Use when analyzing any pooled CRISPR screen end-to-end, matching the hit-calling method to the experimental design, integrating copy-number correction into the pipeline, or branching the workflow for single-cell, combinatorial, base-editor, prime-editor, or in vivo variants.
development
Transcribe DNA to RNA and translate to protein using Biopython, with NCBI codon-table selection, CDS validation, and six-frame ORF finding. Use when converting a CDS or ORF to its amino-acid sequence, selecting a non-standard (mitochondrial, bacterial, ciliate) genetic code, validating a coding sequence, or scanning all reading frames.